JEJoseph Elijah

Joseph Elijah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph Elijah has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Allison Holdsworth

    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, USA

    1 shared publication
  • Christina Billias

    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, USA

    1 shared publication
  • Eugene Przespolewski

    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, USA

    1 shared publication
  • Grace K. Dy

    Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, USA

    1 shared publication
  • Jeffrey Baron

    University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, USA

    1 shared publication
  • Katy Wang

    Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA

    1 shared publication

Latest Publications

  • Open Access

    Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?

    by Joseph Elijah, Prantesh Jain, Allison Holdsworth, Jeffrey Baron, Eugene Przespolewski, Katy Wang, Kristopher Attwood, Christina Billias, Grace K. Dy

    Background: Trilaciclib, in comparison to placebo plus carboplatin, etoposide, ± atezolizumab (PEA), has shown significant reductions in incidence of severe neutropenia (SN) among patients with extensive-stage small cell lung cancer (ES-SCLC). Despite these findings, real-world utility remains limited. Methods: A single-center quasi-experimental study compared trilaciclib + PEA (PEAT) versus PEA in ES-SCLC patients. The study period ranged from April 1, 2021 to July 31, 2022, for the PEAT recipients and February 1, 2020, to February 28, 2021, for PEA recipients. The primary endpoint evaluated was incidence of SN after cycle 1 and during the treatment period. Secondary endpoints included measures related to myelopreservation and patient outcomes. Results: Among 34 PEAT and 44 PEA patients, baseline characteristics were similar, except for a higher median age (69 vs 64 years) and more males (64.7% vs 38.6%) in the PEAT cohort. The PEAT cohort exhibited a lower SN rate (3%) versus the PEA cohort (18%), with statistical significance demonstrated on multivariate analysis (p = 0.015). Additionally, the PEAT cohort also demonstrated significant reductions in red blood cell transfusion requirements (3% vs 23%; p = 0.02), grade 3–4 anemia (6% vs 25%; p = 0.03), and grade 3–4 thrombocytopenia (0% vs 11%, p = 0.045). Conclusion: Trilaciclib, in combination with PEA, demonstrated an improvement in the safety profile without compromising survival outcomes in ES-SCLC patients. These findings underscore the potential benefits of incorporating trilaciclib in real-world clinical settings for enhanced patient care.